Saphnelo for Systemic Lupus Erythematosus

This study aims to gather information about the long-term safety and effectiveness of a medicine called Anifrolumab in patients with systemic lupus erythematosus (SLE), a condition where the immune system attacks healthy tissue. The study focuses on patients who do not respond well to existing treatments. This is important because it can help determine if Anifrolumab is a safe and effective option for these patients in real-life settings, potentially providing a new avenue for managing their condition. Participants in the study will receive Anifrolumab through an intravenous infusion, which means the medicine will be delivered directly into their bloodstream. The study will monitor the occurrence of adverse drug reactions (ADRs), which are unwanted effects from the medication. Specifically, it looks at the likelihood of issues such as herpes zoster, serious infections, allergic reactions, cancer, and hepatitis B virus reactivation. Understanding these risks is crucial to ensure the treatment's safety for long-term use.